Toronto-based Fibrocor Therapeutics has been established by Evotec and MaRS Innovation to develop disease-modifying therapeutics against fibrotic diseases.
"Fibrosis continues to be an area of huge unmet medical need,” commented Dr Mario Polywka, Chief Operating Officer of Evotec.
We are delighted to be a part of the launch of Fibrocor together with MaRS Innovation and look forward to working with our new partners in this exciting venture." Established in 2008, MaRS Innovation is supported by the Government of Ontario, through the Ontario Centres of Excellence.
In November 2016 one of MaRS’s leading portfolio companies, Triphase Accelerator, sold its first investigational anticancer compound, marizomib, to Celgene.
"We are building on our recent success of Triphase in the area of oncology and applying it to a new therapeutic cluster in the area of fibrosis, stated Dr Rafi Hofstein, president and CEO of MaRS, commenting on the establishment of Fibrocor.